awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38878906-29F1F18B-6AE7-473A-A772-26487AF5F7D3
Q38878906-29F1F18B-6AE7-473A-A772-26487AF5F7D3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38878906-29F1F18B-6AE7-473A-A772-26487AF5F7D3
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges
P2860
Q38878906-29F1F18B-6AE7-473A-A772-26487AF5F7D3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38878906-29F1F18B-6AE7-473A-A772-26487AF5F7D3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e6de619a6a3018e05e5aef1e1d4cadf503073746
P2860
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.